Apellis APLS 深 沪
等待开盘 07-02 09:30:00 美东时间
41.03
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 41.03
- 总市值 525.18万
- 52周最高 41.14
- 市盈率 静 237.99
- 换手率 0.00%
- 52周最低 16.61
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 94.75
- 量 比 0
- 振 幅 0.00%
- 历史最低 11.45
- 每 手 1
- 风险率 6.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多渤健：尼达姆与公司高层会议核心要点
Needham分析师阿米·法迪亚在与渤健（Biogen）管理层会面后，将其目标价从255美元上调至256美元，维持“买入”评级。 核心业务相关要点： Spi...
06-29 23:32
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout June 26 (Reuters) - Biogen BIIB.O said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it purchased for
06-26 21:24
Biogen's Base Is Declining — But 8 Pipeline Readouts Could Flip The Story
Biogen analyst upgraded to Buy, cites key growth drivers as Leqembi, Spinraza, Syfovre, and Empavelli and other catalysts.
06-09 00:08
Biogen, UCB lupus drug dapirolizumab pegol meets phase 3 goal
UCB and Biogen (BIIB) on Monday said that their investigational drug dapirolizumab pegol met the primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a ...
06-01 13:25
超7亿美金闪电融资，自免新星正面硬刚巨头
本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。 新锐自免...
05-20 09:34
大洗牌前夜：翻阅十大药企最新财报后，我看见权力正在转移
2026年第一季度的财报已基本出齐，全球制药业的竞争位次经历了一轮深刻的重构。将三组关键数据并列观察，格局的轮廓便会自动浮现。 第一组：礼来单季营收198亿美元...
05-18 16:29
Cantor Fitzgerald Suspends Neutral Rating on Apellis Pharmaceuticals
Cantor Fitzgerald suspends Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS).
05-15 20:28
Why Is Biogen Stock Falling Thursday?
Biogen shares slip after mixed Phase 2 Alzheimer's data, but analysts remain optimistic on diranersen's cognitive benefits.
05-14 23:57
美股夜盘 | Penguin Solutions Incorporation涨14.66%，Nextpower涨10.21%
Penguin Solutions Incorporation涨14.66%；Nextpower涨10.21%；Robinhood Ventures Fund I涨9.74%
05-13 10:01
Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy
FDA extends review for Biogen's Leqembi Iqlik for early Alzheimer's disease to August 2026.
05-08 23:31
